TARRYTOWN, N.Y. (AP) -- Regeneron Pharmaceuticals Inc. said Tuesday that European Union regulators approved its eye drug Eylea.
The European Commission approved the drug as a treatment for "wet" age-related macular degeneration, the leading cause of blindness in the elderly. U.S. regulators approved Eylea as a treatment for wet AMD in 2011. Earlier this year they approved it as a treatment for another eye condition called central retinal vein occlusion.
Eylea was also approved this year in Japan, Australia, and Switzerland.
Shares of Regeneron rose 7 cents to $174.46 in morning trading.